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ABSTRACT
Introduction Cell therapy has been studied in many 
different research domains. Cellular replacement of 
damaged solid tissues is at an early stage of development, 
with much still to be understood. Systematic reviews and 
meta- analyses are widely used to aggregate data and find 
important patterns of results within research domains.
We set out to find common biological denominators 
affecting efficacy in preclinical cell therapy studies for 
renal, neurological and cardiac disease.
Methods We used datasets of five previously published 
meta- analyses investigating cell therapy in preclinical 
models of chronic kidney disease, spinal cord injury, stroke 
and ischaemic heart disease. We transformed primary 
outcomes to ratios of means to permit direct comparison 
across disease areas. Prespecified variables of interest 
were species, immunosuppression, cell type, cell origin, 
dose, delivery and timing of the cell therapy.
Results The five datasets from 506 publications yielded 
data from 13 638 animals. Animal size affects therapeutic 
efficacy in an inverse manner. Cell type influenced efficacy 
in multiple datasets differently, with no clear trend for 
specific cell types being superior. Immunosuppression 
showed a negative effect in spinal cord injury and a 
positive effect in cardiac ischaemic models. There was a 
dose–dependent relationship across the different models. 
Pretreatment seems to be superior compared with 
administration after the onset of disease.
Conclusions Preclinical cell therapy studies are 
affected by multiple variables, including species, 
immunosuppression, dose and treatment timing. These 
data are important when designing preclinical studies 
before commencing clinical trials.
INTRODUCTION
Stem and progenitor cells have emerged as 
potential therapies in many different areas of 
medicine. They have the capacity to replace 
or stimulate repair of damaged tissue, can 
be used to study human development and 
disease, and serve as a test bed for discovering 
new drugs and gene therapies. Cellular prod-
ucts as a therapeutic have provided new para-
digms of regeneration for many organs, espe-
cially organs that do not heal easily, such as 
the brain, like the brain, heart, kidney, carti-
lage and eye.1 In light of the overwhelmingly 
positive results seen in preclinical studies, cell 
therapy is being translated into the clinic in 
multiple research fields. The rationale for 
transplanting these stem and progenitor cells 
is bifold: potentially replacing lost tissue and 
predominantly supporting the surviving cells 
through paracrine mechanisms or modula-
tion of the immune response.2 3 Study of these 
mechanisms points towards soluble growth 
factors, cytokines and extracellular vesicles as 
major mediators in these processes.
Preclinical studies are often the starting 
point for such promising new therapies. 
Animal experiments allow exact control of 
experimental conditions and access to post-
mortem material with fewer restrictions 
than human trials, while maintaining the 
complexity of a whole organism. Preclinical 
models of disease have been standardised 
to a large extent and are ideally comparable 
across research centres. Rodent models are 
most frequently used, as rodents are easy to 
handle, are cost- effective to maintain, have a 
short generation span and the availability of 
inbred strains theoretically allows for great 
experimental reproducibility and stable 
breeding of genetically modified animals. On 
the other hand, it is argued that large animal 
models show greater similarity to human 
physiology. Studies in, for example, pigs are 
Strengths and limitations of this study
► Direct comparison of different research fields
through meta- analytical use ratio of means.
► Outcomes of preclinical cell therapy studies in mul-
tiple fields are influenced by experimental choices
like animal size, dose and timing of the intervention.
► Since this is a new analysis on existing datasets, a
systematic new search was not performed.
► There is no prepublished analysis protocol.
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therefore often used as an intermediate essential ‘confir-
matory step’ in the translational axis towards human 
application.4
In the preclinical application of cell therapies, multiple 
meta- analyses have been performed on studies using 
models of renal,5 neurological6 7 and cardiac disease 
models.8 9 Since the paracrine mode of action is hypo-
thetically similar for these stem cell and progenitor cell 
injections, common effects and effect modifiers for these 
and future cell therapy research fields could be present 
in these datasets. In this paper, we focus on potential 
common denominators in these studies (eg, animal size, 
cell origin, cell type and immunosuppression) to look 
for certain overlapping cell therapy characteristics across 
disease entities. Subsequently, we searched for all phase 
III trials in these diseases, to see which research fields are 
getting close to clinical application.
METHODS
We used the original data of five previously published 
preclinical systematic reviews containing meta- analyses on 
the effect of stem and progenitor cell therapy in chronic 
kidney disease (CKD),5 stroke,6 spinal cord injury (SCI)7 
and myocardial infarction (MI).8 9 The CKD dataset 
comprises all controlled studies (identified by searching 
PubMed and EMBASE in January 2014) reporting the 
efficacy of cells or cellular products in animal models of 
CKD. Primary outcomes were blood pressure, urinary 
protein, plasma creatinine, plasma urea and glomerular 
filtration rate. For the present analysis, we prespecified 
blood pressure and urinary protein as our outcomes. The 
stroke dataset comprises all controlled studies (identified 
by searching PubMed, EMBASE, BioSIS and ISI Web of 
Science in October 2009) reporting the efficacy of allo-
genic or autologous stem cells in animal models of focal 
cerebral ischaemia expressed as a change in structural 
(infarct size) or neurobehavioural outcome. Studies 
using interventions to mobilise endogenous stem cells 
were excluded. The SCI dataset comprises all controlled 
studies (identified by searching PubMed, EMBASE and 
ISI Web of Science in December 2011) reporting the effi-
cacy of 45 different stem cell types in animal models of 
SCI induced by transection, hemisection, compression or 
contusion with outcome assessed by change in motor or 
sensory behaviour. This was the only dataset to rely solely 
on behavioural (motor and sensory) outcomes reflecting 
normal reporting standards for this field where lesion 
volume is difficult to delineate. The MI datasets included 
both acute and chronic models of ischaemic cardiomyo-
pathy. One dataset8 included all animal studies in large 
animals (identified by searching PubMed and Embase 
in January 2013) that used cell therapy (myoblasts, bone 
marrow cells, mesenchymal stem cells and cardiac stem 
cells (CSCs)) in comparison to a control group. Primary 
outcome studied was ejection fraction (EF). The other 
MI dataset10 studied all animal models (identified by 
searching PubMed and Embase in October 2015) using 
CSCs in comparison to a placebo- controlled group (PBS/
vehicle/other cells). The primary outcome studied was 
EF.
For the CKD, stroke and MI datasets, structural 
outcomes were reported as continuous variables. 
Behavioural outcomes were described by a number of 
ordinal scoring systems specific for the field as described 
in detail in each paper. We converted all outcome 
measures to ratios of means (ROMs) and its SE, based on 



















We specifically choose this effect size measure to resolve 
differences between the effect size measures used in the 
original meta- analyses, in terms of their magnitude and 
direction of effect, thus allowing these to be pooled. 
Interestingly, the ROM does not rely on SD, which can 
differ a lot in preclinical studies and potentially can make 
other standardised measures like standardised mean 
differences less reliable. The ROM will represent a rela-
tive gain compared with a control group and therefore 
is only usable to pool data from controlled experiments. 
To standardise our comparison of the different outcome 
measures further, we looked at the direction of all the 
outcome measures and if necessary, transformed this 
value, to make sure the potential beneficial effect of cell 
therapy would show a value <1.0. For the cardiac data-
sets (EF), SCI dataset (neurobehavioural scores), stroke 
dataset (infarct size reduction) and CKD dataset (blood 
pressure), an increase in outcome measure indicates a 
favourable response to cell therapy, so these outcomes 
where not transformed. The urinary protein measure-
ments (less urinary protein means a favourable response) 
were converted, using 1/ROM. Thus, throughout this 
paper, ROM <1.0 indicates a favourable outcome in the 
therapy group, compared with the control group.
By using ROMs, we provide a common effect size 
measure across the outcomes in different models. In 
order to study effect modifiers and explore sources of 
heterogeneity, variables of interest were:
1. Species, stratified as mice versus rats versus dogs versus
sheep versus pigs versus other species.
2. Cell origin, stratified as autologous/syngeneic versus
allogeneic versus xenogeneic.
3. Cell type, stratified as bone marrow derived versus
mesenchymal stem cells versus blood derived versus tis-
sue- resident cell versus pluripotent cell (e.g. induced
pluripotent stem cells (iPSC) or embryonic stem cells
(ESC)) versus other cell types.
4. The use of immunosuppression, stratified as drug in-
duced versus genetic.
5. Cell dosage, per kg, corrected through allometric scal-
ing.
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6. Delivery method, stratified as peripheral infusion ver-
sus local infusion (eg, in a coronary artery, renal artery,
cerebral artery) versus direct injection (eg, injection
in/around the organ of interest).
7. Tand timing method, stratified as pretreatment ver-
sus acute (<24 hours after damage), versus subacute
(1–7 days after the damage versus chronic (>7 days af-
ter the injury).
For species, we combined gerbils, marmosets and
rabbits in one ‘Other’ group, as these species were used 
in <5 studies in total over all datasets (n in total for 
this group). We are aware of the important differences 
between these species and will not draw any conclu-
sions from these groups. For cell type, we combined less 
frequently used cell types in one ‘other cell type’ vari-
able, including amniotic fluid cells, dermal cells and hair 
follicle cells. Combinations of different cell types were 
mentioned separately. In the CSC dataset, multiple tissue- 
specific cells were used. Only for the univariable analysis 
we separated these, thereafter they will all be seen as 
equal tissue- specific cells. To make a comparable variable 
for dosage across studies, we corrected the variable for 
the weight of the animal and used allometric scaling. For 
the different species, we used standardised weights; mice 
(25 g), rats (300 g). ‘Other’ group (gerbils/marmosets/
rabbits) (4000 g), dogs (20 000 g), sheep (12 000 g) and 
pigs (60 000 g). The dose was divided by the number of 
grams of the species to the power 0.75 for allometric 
scaling (number of cells / (weightˆ0.75)). Variables were 
retrieved from the original publications or recoded if not 
already present in the desired format.
In our analyses, we included all available data but 
grouped subsets of data known to be small under one 
group, unless it was a combination of different cellular 
products or immunosuppression. We are aware of poten-
tial spurious effects in meta- regression when comparing 
small groups.12 However, because the original experi-
mental description coding remains, when performing the 
multivariable meta- analysis some of these smaller subsets 
of data re- emerge. For completeness, we judged that it 
was better to retain them in the datasets but not draw 
conclusions from them, than to discard them, hence their 
appearance in some of our graphs and tables.
The search for Phase III trials was performed on 1 
November 2019 on the website https://www. clinicaltrials. 
gov/. Search terms were “stem cells” in combination with 
the disease of interest (“Renal Failure”, “Kidney Failure”, 
“Amyotrophic Lateral Sclerosis”, “Motor Neuron Disease”, 
“Parkinson”, “Alzheimer”, “Huntington”, “Stroke”, 
“Spinal Cord Injury”, “Myocardial Infarction” and “Heart 
Failure”). All retrieved studies were screened for their 
relevance. Trial registration numbers of relevant studies 
were recorded, regardless of their status.
Statistical analysis
The variable dose/kg (already corrected for allometric 
scaling) was log transformed to correct for a non- normal 
distribution of the data. Random- effects meta- analysis was 
performed for all datasets. Univariable meta- regression 
was performed for the chosen variables with the original 
outcome measure from the study and the new natural 
log of our generated ROMs and its SE. Natural Logs (of 
ROMs) were transformed back for proper visualisation 
and interpretation in figures and tables. In figures, we 
show the metaregression of univariable analyses of the 
variable under study. For the dose- response figure, we 
used metaregression in combination with cubic splines 
(set to three splines) to properly visualise the association.
Because of known concerns about bias towards no 
effect with sample sizes for ROMs,11 we tested the effect 
of the variable ‘number of animals’ per comparison on 
both the original outcomes and ROMs for all datasets. We 
also summarised the number of animals for the different 
species in the datasets, to analyse if the variable species 
could potentially influence ROMs merely through the 
number of animals used, as one might expect studies in 
larger animals (and their comparisons within the study) 
to have smaller sample sizes compared with studies in 
small animals.
Multivariable analysis with all variables of interest was 
performed for every dataset individually and for all data-
sets combined for both original outcomes and ROMs. 
In the final analysis for all datasets, we corrected for any 
influence of the datasets themselves by using them as an 
independent variable. Post hoc testing was performed 
using a Wald test. Three studies from one dataset (on 
MI)8 were removed for this combined analysis, as these
were also present in another dataset.9 For the multivari-
able analyses, p values for the individual variables within
the multivariable meta- regression are reported. Although
we reported all p values, we will only interpret post hoc p
values if the p value for the initial analysis of the variable
is significant. A p<0.01 was considered statistically signif-
icant to reduce the risk of false- positive testing. Since we
are comparing many subgroups, our current analyses can
only be interpreted as hypothesis- generating. Statistical
analyses were performed using R V.3.1.213 with the addi-
tional metafor, lattice, rms and readxl packages.14–17 and
using Stata V.13.1.18
RESULTS
The combined data from 5 datasets yielded 506 publica-
tions with a total of 13 638 included animals. Descriptive 
statistics of all studies are depicted in table 1.
The animals used in these studies range from mice and 
rats, most commonly used in models of CKD, stroke, SCI 
and MI, to rabbits, gerbils and marmosets in the neuro-
logical studies and pigs and sheep predominantly used 
in models of MI. Regardless of the primary outcome 
measure used, stem and progenitor cell therapy appeared 
to improve the outcome in all disease models (table 1). 
Most common control groups where vehicle treated or 
PBS treated. Only a minority of papers did not include a 
proper placebo- treated control group.
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To assess the robustness of our chosen effect size measure 
the ROM, we generated all analyses for the primary 
outcome (either a raw mean difference, standardised 
mean difference or normalised mean difference) and 
compared them to ROMs (see online supplemental tables 
1–6). The ROMs generated similar directions of effect 
and effects of most subgrouping variables compared with 
the those found with the effect size measures used in the 
original meta- analyses, deeming ROMs an appropriate 
effect size measure for our analyses.
Effect of ROMs and number of animals per comparison
The conversion to ROMs resulted in similar directions 
of effects of the different variables in our subgroup anal-
yses, compared with the original outcomes from the 
papers (online supplemental tables 1–5). The number 
of animals per group was not associated with significant 
outcomes for ROMs, compared with the originally used 
outcomes (online supplemental table 7). The number 




We stratified our dataset according to species. Small 
animals such as mice and rats appear to consistently have 
larger effect sizes across all disease models when analysed 
with ROMs, compared with larger animals such as dogs, 
or pigs (figure 1, online supplemental table 1–6). Only 
the SCI dataset did not show a similar trend (figure 1D) 
univariably.
Multivariable analysis
In the multivariable analyses, species was of no significant 
importance anymore in most datasets (online supple-
mental tables 1–6) when analysed with ROMs.
Cell type
Univariable analysis
Cell type did not seem to influence any outcome in 
CKD univariably (p=0.87 and p=0.04, figure 2A,B, online 
supplemental table 1a and 2a). In the stroke dataset, 
cell type did explain part of the heterogeneity, with 
brain- specific cell types performing worse, especially 
compared with pluripotent cells and mesenchymal stem 
cells (p=0.0007, figure 2C, online supplemental table 3a). 
In the SCI dataset, there were no significant differences 
(p=0.08, figure 2D, online supplemental table 4a). In 
MI studies in large animals, there was no difference in 
efficacy between different cell types (p=0.22, figure 2E, 
online supplemental table 5a). In the MI studies in small 
animals using CSCs, cardiosphere- derived cells were more 
effective compared with Sca-1+ cells (figure 2F, online 
supplemental table 6a).
Multivariable analysis
In multivariable analyses, there were no significant differ-




Cell source did not appear to affect the outcomes in the 
CKD, SCI and large animal MI datasets (figure 3A,B,D,E). 
In the stroke data, autologous cells seemed more effica-
cious compared with allogeneic and xenogeneic stem 
cells (p=0.0003, figure 3C, online supplemental table 3a). 
As reported previously,9 in the cardiac dataset with CSCs, 
autologous cells seemed less efficacious compared with 
the other cell types (p=0.005, figure 3F, online supple-
mental table 6a).
Multivariable analysis
In multivariable analyses, the autologous cells still 
performed better than the allogeneic and xenogeneic 




The use of ciclosporin A seems to reduce the benefi-
cial effects of stem cell treatment on neurobehavioural 
scores after SCI (p=0.0005, figure 4C, online supple-
mental table 4a). In small animal models from the 
CSC dataset, it seems that stem cells are more effective 
in genetically modified immunodeficient mice (SCID 
Table 1 Summary of baseline characteristics of included systematic reviews
Papazova et al5 Lees et al6 Antonic et al7 Jansen Of Lorkeers et al8 Zwetsloot9
Disease type Nephrology Stroke SCI MI (large animals, all cell 
types)
MI (all animals, cardiac 
stem cells)
No of studies 71 117 156 82 80
No of comparisons 31/106* 192 319 125 109
No of animals 1813 2704 5736 1415 1970
Primary outcome Blood pressure 
and urinary protein
Infarct volume Neurobehavioural 
outcomes
Cardiac function (EF) Cardiac function (EF)
Overall effect size 0.60 (0.34–0.87)† 24.8% (21.5–28.1)‡ 27.3% (25.1% to 29.4%)‡ 8.3% (7.1%–9.5%) 10.7% (9.4%–12.1%)
*31 comparisons for blood pressure, 106 for urinary protein.
†Primary outcome for blood pressure converted to a standardised mean difference.
‡Primary outcome for infarct volume and neurobehavioural scores converted to a normalised mean difference.
EF, ejection fraction; MI, myocardial infarction; SCI, spinal cord injury.
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or athymic mice), compared with immunocompetent 
animals (p=0.001, figure 4E, online supplemental table 
6a). In the other datasets, immunosuppression did not 
affect treatment efficacy. For the CKD dataset and blood 
pressure outcomes, there were no studies using any type 
of immunosuppression.
Multivariable analysis
In multivariable analyses, ciclosporin A still showed the 
same negative effect in the SCI dataset (p=0.002, online 
supplemental table 4a). In the stroke dataset, ciclosporin 
A showed the opposite effect in multivariable analysis: 
the beneficial effect of stem cell treatment was increased, 
compared with studies when there was no use of immu-
nosuppression (p=0.0005, online supplemental table 3a).
Cell dose
Univariable analysis
In all but the SCI dataset and the CKD blood pres-
sure dataset, higher cell dose (corrected for metabolic 
weight) was significantly associated with better outcomes 
(figure 5). In every dataset, the ROM was <1, suggesting 
similar effects in all datasets with more cells meaning 
more benefit (figure 5 and online supplemental table 
1–6). For the SCI dataset, the graph was more informa-
tive without back- transforming the ROM. For clarity, we 
added the figure with the transformed ROMs as an online 
supplemental figure 1.
Multivariable analysis
In multivariable analyses, cell dose significantly affected 
the primary outcome in the CKD urinary protein dataset 
and the stroke dataset. The direction of the effect was still 
the same (ROM<1), showing better outcomes if more 
cells were used (table 2).
Delivery strategy
Univariable analysis
The mode of delivery influenced stem cell treatment effi-
cacy in most datasets in univariate analysis. In the CKD 
Figure 1 Meta- regression analyses with regard to cell therapy efficacy in different species quantified by (A) urinary protein 
(CKD), (B) blood pressure (BP) difference (CKD), (C) infarct size (stroke), (D) neurobehavioural scores (SCI), (E) ejection fraction 
(large animal MI studies), (F) ejection fraction (CSC MI studies). outcomes are expressed in ROMs. Vertical p value represents 
the total meta- regression. Horizontal p values are significance compared with an assumed ‘no effect’. CKD, chronic kidney 
disease; CSC, cardiac stem cell; MI, myocardial infarction; ROMs, ratios of means; SCI, spinal cord injury; LVEF, left ventricular 
ejection fraction.
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urinary protein dataset, direct injection was superior over 
local infusion or peripheral infusion (p=0.01 and p=0.001, 
respectively, figure 6A, online supplemental table 1a). In 
the CKD blood pressure dataset, numbers were too small 
to report an accurate difference between direct injection 
and other groups, although the comparison reached 
statistical significance (online supplemental table 2a). In 
the stroke dataset, peripheral infusion was superior over 
direct injection (p=0.003, figure 6C, online supplemental 
table 3a). In the SCI dataset, direct injection and periph-
eral infusion showed better outcomes compared with 
local infusion (p<0.001 for both, figure 6D, online supple-
mental table 4a). In the cardiac large animal dataset, 
direct injection was superior over local infusion (p=0.01, 
figure 6E, online supplemental table 5a).
Multivariable analysis
In multivariable analyses, cell delivery still significantly 
influenced the CKD urinary protein dataset and SCI 
dataset. In the CKD urinary protein, the effect of direct 
injection was still superior over local or peripheral infu-
sion (p=0.01 and p=0.003 respectively, online supple-
mental table 1a). In the SCI dataset, direct injection and 
peripheral infusion remained superior compared with 




Timing of administration of cell therapy significantly 
affected the outcome in the CKD blood pressure dataset, 
showing an increased efficacy after acute administration, 
compared with administration in the chronic setting 
(p=0.002, figure 7B, online supplemental table 2a). In 
the stroke dataset, pretreatment was superior over all 
other administration timings (p<0.001, figure 7C, online 
supplemental table 3a). Acute and subacute administra-
tions were also better than administration in the chronic 
setting (p<0.001 and p<0.001, respectively, figure 7C, 
online supplemental table 3a). In the CSC dataset, acute 
Figure 2 Meta- regression analyses with regard to cell therapy with different cell types quantified by (A) urinary protein (CKD), 
(B) blood pressure (BP) difference (CKD), (C) infarct size (stroke), (D) neurobehavioural scores (SCI), (E) ejection fraction (large
animal MI studies), (F) ejection fraction (CSC MI studies). Outcomes are expressed in ROMs. Vertical p value represents the
total meta- regression. Horizontal p values are significance compared with an assumed ‘no effect’. CKD, chronic kidney disease;
CSC, cardiac stem cell; MI, myocardial infarction; ROMs, ratios of means; SCI, spinal cord injury; LVEF, left ventricular ejection
fraction.
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administration was also associated with better outcomes 
when compared with administration in the chronic 
setting (figure 7F, online supplemental table 6a).
Multivariable analysis
In multivariable analysis, time of administration still 
impacted the outcome significantly (p<0.0001) in the 
stroke dataset, showing a greater effect of pretreatment 
with cell therapy compared with either acute, subacute or 
chronic administration (online supplemental table 5a).
Analysis of the combined datasets
Univariable analysis
In univariable analysis, mice and rats are performing 
significantly better compared with pigs (p=0.001 for 
both). Also, mice performed better than rats (p=0.001). 
There was so significant difference for cell type (p=0.09), 
cell origin (p=0.09), cell origin (p=0.84) or immunosup-
pression (p=0.01). Higher dose was significantly associ-
ated with better outcomes (p=0.0003). For delivery strate-
gies, direct injection and peripheral infusion performed 
better than local infusion (p=0.002 and p=0.001, 
respectively). For time of administration, pretreatment 
performed better than chronic administration and suba-
cute administration (p=0.001 and p<0.001, respectively). 
There were significant differences between the different 
datasets univariably (see online supplemental table 9).
Multivariable analysis
The multivariable analysis of all datasets combined 
revealed that cell dose (p=0.001), cell type (p=0.001) and 
time of administration (p=0.0001) share significant effects 
on stem cell treatment efficacy in all datasets. For cell 
dose, this means the higher the dose, the better the effect 
of cell therapy regardless of the disease model (p=0.001). 
For cell type, this was apparent for tissue- specific cells, 
being less efficacious compared with pluripotent cells 
(p=0.006), bone marrow- derived cells (p=0.001) and 
mesenchymal stem cells (p=0.001). For time of adminis-
tration, pretreatment with cell therapy resulted in greater 
benefits compared with administration in the acute, 
Figure 3 Meta- regression analyses with regard to cell therapy from different cell sources quantified by (A) urinary protein 
(CKD), (B) blood pressure (BP) difference (CKD), (C) infarct size (stroke), (D) neurobehavioural scores (SCI), (E) ejection fraction 
(large animal MI studies), (F) ejection fraction (CSC MI studies). Outcomes are expressed in ROMs. Vertical p value represents 
the total meta- regression. Horizontal p values are significance compared with an assumed ‘no effect’. CKD, chronic kidney 
disease; CSC, cardiac stem cell; MI, myocardial infarction; ROMs, ratios of means; SCI, spinal cord injury; LVEF, left ventricular 
ejection fraction.
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subacute or chronic setting (=0.0001). Furthermore, 
also the different datasets showed a significant effect on 
our outcome measure (p=0.0006), with the CKD Blood 
pressure dataset performing worse compared with the 
CKD urinary protein dataset (p=0.001), the CSC dataset 
(p=0.01) and the SCI dataset (=0.01). The SCI dataset 
performed better compared with the stroke dataset 
(p=0.003). The estimated ROMs and confidence intervals 
are provided in online supplemental table 9.
Current phase III trials in stem and progenitor cell therapy
Since we wanted to know the stage in which the different 
cell therapy fields are right now, we searched for all phase 
III trials in each disease. Our search retrieved 34 phase III 
trials, of which 25 were in the cardiac field (table 3). The 
other nine trials are in different neurological diseases. No 
phase III studies for kidney diseases were found through 
our search.
Out of all of these studies, 14 have been registered 
as completed (2 in neurological diseases, 12 in cardiac 
diseases), while two studies were terminated early. The 
other 28 studies are either at the stage of recruiting 
patients, or have already passed their completion date, 
but have not updated their status on  ClinicalTrials. gov.
DISCUSSION
In this paper, we show using meta- analysis that experi-
mental design choices lead to outcome trends that are 
universal across preclinical studies of stem and progen-
itor cell therapy in models of kidney, neurological and 
cardiac disease. Attention to these choices is needed to 
optimise research in this field and ensure realistic expec-
tations of tested therapeutics. This analysis should be 
considered hypothesis generating. Nevertheless, p values 
are provided to help researchers prioritise future hypoth-
esis testing.
Species most strikingly affected the efficacy of cell 
therapy in univariable analyses, with decreasing treat-
ment efficacy going from rodents to larger mammals. 
There was no important effect of species on our outcomes 
when multivariable analysis was applied, arguing that 
Figure 4 Meta- regression analyses with regard to cell therapy stratified for the use of immunosuppression, quantified by (A) 
urinary protein (CKD), (B) infarct size (stroke), (C) neurobehavioural scores (SCI), (D) ejection fraction (large animal MI studies), 
(E) ejection fraction (CSC MI studies). Outcomes are expressed in ROMs. Vertical p value represents the total meta- regression.
Horizontal p values are significance compared with an assumed ‘no effect’. CKD, chronic kidney disease; CSC, cardiac stem
cell; MI, myocardial infarction; ROMs, ratios of means; SCI, spinal cord injury; LVEF, left ventricular ejection fraction.
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choice of species might be correlated with multiple other 
factors that influence cell therapy efficacy. Large animal 
trials have an important part to play in the evaluation 
of new therapies destined for human use. It is generally 
argued that larger animals more closely resemble human 
anatomy, physiology and ultimately reaction to therapy.4 
Comparing our univariable and multivariable analyses, 
we cannot conclude whether it is the actual animal size 
or other factors that come with large animal experiments 
that affects efficacy. Large animal studies might be asso-
ciated with different experimental choices with regard to 
physiological monitoring and ethically mandated inter-
ventions, therapeutic delivery and cell dose. Furthermore, 
it has been proposed that large animal studies resemble 
Figure 5 Dose- response curves with regard to cell therapy quantified by (A) urinary protein (CKD), (B) infarct size (stroke), (C) 
neurobehavioural scores (SCI), (D) ejection fraction (large animal MI studies), (E) ejection fraction (CSC MI studies). outcomes 
are expressed in the natural log of ROMs. The circles resemble single studies and their size resembles the weighing of 
the study. The bigger the circle, the smaller the SE of the study. CKD, chronic kidney disease; CSC, cardiac stem cell; MI, 
myocardial infarction; SCI, spinal cord injury.
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human clinical trials better with regard to blinding, 
randomisation and susceptibility to bias, although to 
our knowledge, this has never been proven. A theoret-
ical limitation of using ROM is a potential bias towards 
detecting no effect when study sizes are small.11 However, 
as we could find no evidence for a relationship between 
ROM and number of animals per experimental cohort for 
this (online supplemental table 7), or our other compar-
isons, we do not believe that our finding reflects limited 
sampling in studies using larger species.
Interestingly, in almost all datasets, tissue- specific cell 
types (eg, a progenitor cell that resides in the organ of 
interest) did not show clear benefits over first genera-
tion cells like bone marrow- derived cells, mesenchymal 
stem cells, circulating cells or pluripotent cells, which is 
in line with current perspectives.19 20 In our multivariable 
analysis of all datasets combined, tissue- specific cells even 
showed less efficacy compared with other cell products, 
although this result might be predominantly driven by 
the neurological datasets. Of note, the modes of action 
might also be different for the different cell types under 
study, as a paracrine cell and a self- integrating ‘residen-
tial’ cell type could benefit a damaged organ differently. 
In the cardiac field, multiple preclinical studies hinted 
on superior effects of combinations of progenitor cell 
types, hypothetically making use of multiple cell- specific 
abilities.21–24
In all these different disease models, stem and progen-
itor cell therapy seems to provide a comparable gain of 
function, regardless of cell origin. As shown previously in 
the cardiac field, xenogeneic cells might show less benefit 
than allogeneic or autologous/syngeneic cell sources.25 
Allogeneic and autologous cells have shown comparable 
benefits,25 with the same proposed mechanisms, as is 
confirmed by our analyses.
Immunosuppression has shown to affect treatment effi-
cacy in the datasets on stroke and SCI. In cardiac disease, 
cyclosporine has also been proposed as an agent that 
might affect both disease outcome and cell therapy.26 
However, in our combined datasets and multivariable 
analyses, we could not confirm a common effect of drug- 
induced immunosuppression, which was also not seen 
when directly studied on tissue- specific CSCs.27 Interest-
ingly, recent data argues that the primary effect of cardiac 
cell therapy might be due to a provoked immunological 
reaction, regardless of the cell type and regardless of any 
functionality of the cell therapy.28 This would partially 
explain the comparable outcomes between all different 
cell types. The fact that immune suppression negatively 
influenced cell therapy in the neurological studies might 
also be explained by this phenomenon.
Cell dose showed the same beneficial effect across 
multiple datasets and showed a significant effect in the 
combined multivariable analysis. Although an increase in 
treatment effect with increasing dose was to be expected, 
it remains challenging in both large animal experiments 
and clinical settings to grow billions of cells for a single 
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direct effect of cell dose is shown across multiple diseases. 
The route of cell delivery, whether it was local or periph-
eral, did not affect treatment efficacy in any of the disease 
models. For timing strategies, only pretreatment with cell 
therapy was associated with a better response across all 
datasets, which poses a challenge from a translational 
perspective for the majority of diseases studied.
The factor ‘dataset’, added to the multidataset anal-
ysis to correct for confounding between dataset and 
other variables, showed a significant difference between 
some datasets. While correcting for this factor in our 
multivariable analysis, this suggests that there might 
be some disease- specific heterogeneity for cell therapy 
or collinearity between other variables that cannot be 
grasped in general analyses as the ones conducted in this 
paper. Luckily, most variables of interest showed compa-
rable directions of effect in both the single datasets and 
the general analysis, suggesting similar and generalisable 
effects across diseases.
Figure 6 Meta- regression analyses with regard to cell therapy stratified for the use of time of administration, quantified by (A) 
urinary protein (CKD), (B) infarct size (stroke), (C) neurobehavioural scores (SCI), (D) ejection fraction (large animal MI studies), 
(E) ejection fraction (CSC MI studies). Outcomes are expressed in ROMs. Vertical p value represents the total meta- regression.
Horizontal p values are significance compared with an assumed ‘no effect’. CKD, chronic kidney disease; CSC, cardiac stem
cell; MI, myocardial infarction; ROMs, ratios of means.
12 Zwetsloot P- P, et al. BMJ Open Science 2021;5:e100061. doi:10.1136/bmjos-2020-100061
Open access 
Limitations
Since this is an analysis using existing data, we are 
dependent on the quality of the initial primary datasets 
and their included studies. The included datasets have 
shown high risks of bias within primary studies and publi-
cation bias.5–9 This means that these bias are likely also 
present in our current analysis, which might lead to over-
estimation of effects and is to be taken into consideration 
when interpretating these results.
We should be careful with the interpretation of our 
results, as effect modification through known and 
unknown variables might cause significance without true 
causal relevance. For example, some effects are reduced 
when correcting for other variables of interest, such as 
the effect of immunosuppression and cell origin in the 
MI- CSC dataset. Moreover, differences in the magnitude
of effect sizes between the different disease model data-
sets and the possibility that this reflects differences in
the availability of therapeutic targets amenable to stem
cell therapy, need to be investigated to determine if this
explains why the variable ‘dataset’ accounted for signifi-
cant heterogeneity in our analyses.
In our study, testing for interactions between variables 
was not part of our analysis plan. Nevertheless, with hind-
sight, we can see circumstances where this might have 
been of value. For example, differential interactions 
between the type of stem cell used and degree of inflam-
matory change induced by different models might explain 
the lack of consistency of influence of immunomodula-
tory adjunct therapies. Similarly, we have not attempted 
to correct for prevalence of randomisation, blinding or 
other surrogates of experimental quality.
Of note, the nature of experimental controls used 
across the datasets varied considerably, ranging from no 
(placebo) procedure at all, to vehicle- solution delivery 
or other ‘non- therapeutic cell’ administration. Such vari-
ability is also expected to contribute to heterogeneity and 
subsequent noise in the combined datasets.
For this study, the use of ROMs was essential to provide a 
common denominator for comparisons across sometimes 
Figure 7 Meta- regression analyses with regard to cell therapy stratified for the use delivery method, quantified by (A) urinary 
protein (CKD), (B) infarct size (stroke), (C) neurobehavioural scores (SCI), (D) ejection fraction (large animal MI studies), (E) 
ejection fraction (CSC MI studies). Outcomes are expressed in ROMs. Vertical p value represents the total meta- regression. 
Horizontal p values are significance compared with an assumed ‘no effect’. BP, blood pressure; CKD, chronic kidney disease; 
CSC, cardiac stem cell; MI, myocardial infarction; ROMs, ratios of means; SCI, spinal cord injury; LVEF, left ventricular ejection 
fraction.
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very different field- specific outcome measures. As noted 
earlier, despite a theoretical bias towards no effects when 
study sizes are small, we were unable to detect such a 
correlation in our analysis. Moreover, our transformed 
univariable ROM outcomes agreed well with the general 
direction of effects reported in the original publications 
investigation of heterogeneity.
Stem and progenitor cell therapy research in different stages 
of research
Table 3 summarises ongoing and completed phase III 
trials for stem and progenitor cell therapy in fields of 
nephrology, neuroscience (both neurodegenerative 
and acute disease), MI and heart failure. Although we 
found clear effects of stem and progenitor cell therapy 
and common factors affecting all these different diseases, 
some research areas are already reaching clinical 
endpoints, while others are still in the process of passing 
preclinical phases. Reasons for this discrepancy remain to 
be elucidated, although factors like interest and funding 
might play a role. Current success stories in other disease 
entities, include cellular retinal transplants29 and appli-
cation of stem and progenitor cells or newly generated 
cartilage in degenerated joints,30 offer hope for the 
diseases studied here.
What can we learn from this?
In light of the questioned translatability of rodent 
models in cell therapy research,31 these current analyses 
confirmed the decrease in effect size across multiple 
disease models, when increasing animal size, as reported 
previously for the heart. Cell source and cell type only 
marginally influence efficacy, while immunosuppressive 
effects cannot be generalised to all diseases studied. Why 
the effects are more pronounced for brain diseases is 
unclear. This is the first time that we so clearly show an 
important dose response in all these diseases combined, 
suggesting that large numbers of cells are needed in 
human disease for any effect. The fact that pretreatment 
is most beneficial is of little clinical value, as no disease 
under study will wait to manifest itself for a pretreatment 
to be initiated.
These data emphasises the need for a clear under-
standing of the translational potential of different animal 
models and highlights the importance of calls for stan-
dardisation of animal models and therapeutic approaches 
in all research areas, for which only the neurological 
and cardiac fields have started first initiatives.32–35 This 
study illustrates the importance of cross- domain system-
atic review and meta- analysis as tools for understanding 
important commonalities of value in future preclinical 
and clinical experimental design.
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Disease type
# Phase





Amyotrophic lateral sclerosis/motor neuron disease 2 NCT01933321, NCT03280056




Stroke 3 NCT01716481, NCT02849613, NCT03545607
Spinal cord injury 3 NCT01676441, NCT01873547, NCT03935724
Cardiac disease
Myocardial infarction 16 NCT00279175, NCT00316381, NCT00350766, 
NCT00363324, NCT00501917, NCT00684060, 
NCT00725738, NCT00950274, NCT01187654, 
NCT01392105, NCT01394432, NCT01569178, 
NCT01652209, NCT02323620, NCT02672267, 
NCT03404063,
Heart failure 9 NCT00333827, NCT00462774, NCT00743639, 
NCT00747708, NCT00841958, NCT01693042, 
NCT01759212, NCT02032004, NCT02248532
Bold=completed. Normal font=ongoing/unknown status
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